Deficits in short-term memory binding are detectable in individuals with brain amyloid deposition in the absence of overt neurodegeneration in the Alzheimer's disease continuum

Author(s):Show less -

Cecchini, Mario Amore ^[1] ; Yassuda, Monica Sanches ^{[2, 3]} ; Squarzoni, Paula ^[4] ; Coutinho, Artur Martins ^{[4, 5]} ; Faria, Daniele de Paula ^{[6, 7]} ; de Souza Duran, Fabio Luiz ^[4] ; da Costa, Naomi Antunes ^[4] ; de Gobbi Porto, Fabio Henrique ^[4] ; Nitrini, Ricardo ^[3] ; Forlenza, Orestes Vicente ^[7] ; Dozzi Brucki, Sonia Maria ^[3] ; Buchpiguel, Carlos Alberto ^[5] ; Parra, Mario A. ^[8] ; Busatto, Geraldo F. ^{[4, 6]}

Affiliation

^[1] Univ Edinburgh, Human Cognit Neurosci Psychol, Edinburgh, Midlothian - Scotland

^[2] Univ Sao Paulo, Sch Arts Sci & Humanities, Gerontol, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Sch Med, Neurol, Sao Paulo - Brazil

^[4] Univ Sao Paulo, Lab Psychiat Neuroimaging LIM 21, Hosp Clin, Dept & Inst Psiquiatria, Sch Med, Sao Paulo - Brazil

^[5] Univ Sao Paulo, Lab Nucl Med LIM43, Ctr Med Nucl, Dept Radiol & Oncol, Sch Med, Sao Paulo - Brazil

^[6] Univ Sao Paulo, Nucleo Apoio Pesquisa Neurociencia Aplicada NAPNA, Sao Paulo - Brazil

^[7] Univ Sao Paulo, Sch Med, Dept Psychiat, Lab Neurosci LIM 27, Sao Paulo - Brazil

^[8] Univ Strathclyde, Sch Psychol Sci & Hlth, Glasgow, Lanark - Scotland

• Document type: Journal article
• Source: BRAIN AND COGNITION; v. 152, AUG 2021.
• Web of Science Citations: 0

Abstract

The short-term memory binding (STMB) test involves the ability to hold in memory the integration between surface features, such as shapes and colours. The STMB test has been used to detect Alzheimer's disease (AD) at different stages, from preclinical to dementia, showing promising results. The objective of the present study was to verify whether the STMB test could differentiate patients with distinct biomarker profiles in the AD continuum. The sample comprised 18 cognitively unimpaired (CU) participants, 30 mild cognitive impairment (MCI) and 23 AD patients. All participants underwent positron emission tomography (PET) with Pittsburgh compound B labelled with carbon-11 ({[}C-11]PIB) assessing amyloid beta (A beta) aggregation (A) and 18fluorine-fluorodeoxyglucose ({[}F-18]FDG)-PET assessing neurodegeneration (N) (A -N-{[}n = 35]); A+N-{[}n = 11]; A+ N+ {[}n = 19]). Participants who were negative and positive for amyloid deposition were compared in the absence (A-N vs. A+N-) of neurodegeneration. When compared with the RAVLT and SKT memory tests, the STMB was the only cognitive task that differentiated these groups, predicting the group outcome in logistic regression analyses. The STMB test showed to be sensitive to the signs of AD pathology and may represent a cognitive marker within the AD continuum. (AU)

• FAPESP's process: 14/50873-3 - INCT 2014: National Institute of Biomarkers in Neuropsychiatry
• Grantee: Wagner Farid Gattaz
• Support Opportunities: Research Projects - Thematic Grants
• FAPESP's process: 16/50197-3 - A novel cognitive biomarker to screen for dementia across cultures and countries
• Grantee: Monica Sanches Yassuda
• Support Opportunities: Regular Research Grants
• FAPESP's process: 12/50329-6 - Translational neuroscience of Alzheimer's disease: preclinical and clinical studies of b-amyloid peptide and other biomarkers
• Grantee: Geraldo Busatto Filho
• Support Opportunities: Research Projects - Thematic Grants
• FAPESP's process: 16/07967-2 - Neurocognitive markers for the early and differential diagnosis for Alzheimer´s disease and frontotemporal dementia
• Grantee: Monica Sanches Yassuda
• Support Opportunities: Regular Research Grants